Intermediate-dose intravenous methotrexate with intravenous mercaptopurine is superior to repetitive low-dose oral methotrexate with intravenous mercaptopurine for children with lower-risk B-lineage acute lymphoblastic leukemia: a Pediatric Oncology Group phase III trial.
暂无分享,去创建一个
N. Winick | B. Camitta | R. Nitschke | S. Lauer | J. Shuster | C. Steuber | D. Mahoney | B. Camitta | Donald H. Mahoney